Related Experiment Videos
Multicenter evaluation of the Elecsys CA 125 II assay
W Hubl1, D W Chan, H E Van Ingen
1Institute of Clinical Chemistry and Laboratory Medicine, Dresden-Friedrichstadt-Hospital, Germany.
Anticancer Research
|September 2, 1999
Summary
The Elecsys CA 125 II assay demonstrates excellent technical performance and clinical utility for ovarian cancer. This assay shows high precision and comparability, aiding in disease staging and treatment monitoring.
Area of Science:
- Clinical Chemistry
- Immunoassays
- Oncology Diagnostics
Background:
- The CA 125 biomarker is crucial for monitoring ovarian cancer.
- Evaluating new diagnostic assays is essential for improving patient care.
Purpose of the Study:
- To assess the technical performance and clinical usefulness of the Elecsys CA 125 II assay.
- To compare the Elecsys CA 125 II assay with existing methods.
Main Methods:
- Multicenter evaluation of the Elecsys CA 125 II assay.
- Imprecision studies using control and pooled sera.
- Method comparison with other CA 125 assays (Enzymun-Test, MEIA, IRMA).
Main Results:
- Low imprecision (within-run CVs 0.7–4.8%, between-day CVs 2.4–10.9%).
- Good comparability with other assays, though some showed higher slopes.
- CA 125 II concentrations correlated with ovarian cancer stage.
- Optimal diagnostic efficiency at 150 U/ml (93% specificity, 69% sensitivity).
- Assay shows a broad measuring range (up to 5000 U/ml) and short assay time (18 minutes).
Conclusions:
- The Elecsys CA 125 II assay offers superior analytical performance.
- It is clinically useful for diagnosing and monitoring ovarian cancer.
- The assay's speed and range facilitate efficient patient management.